Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy.

Rectal Cancer Clinical Trial

— CAO/ARO/AIO-16  

Official title:

Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy. A Prospective Phase II Pilot Trial of the German Rectal Cancer Study Group

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03561142
• Other study ID #: CAOAROAIO16
• Status: Recruiting
• Phase: Phase 2
• Start date: June 15, 2018
• Est. completion date: April 16, 2024

Study information

• Verified date: April 2018
• Source: University Hospital Tuebingen
• Contact: Cihan Gani, Dr.
• Phone: +4970712982165
• Email: cihan.gani[@]med.uni-tuebingen.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There is a growing body of evidence that surgery and associated morbidities can be omitted without compromising oncological safety in selected patients who have achieved a clinical complete response after radiochemotherapy. However with standard neoadjuvant treatment regimens the pathological complete response rate lies in the range between 10%-20%, the number of patients qualifying for non-operative management is even lower since the sensitivity of currently available diagnostic measures for predicting the pathological complete response hardly surpasses 50%-60%.The hereby proposed phase II trial CAO/ARO/AIO-16 aims at finding novel and innovative aspects of rectal cancer treatment. According to recently published data the radiochemotherapy regime in the present study with consolidating chemotherapy and delayed assessment of response has the potential to achieve pathological complete rates of approximately 40%. A standardized re-evaluation after consolidating chemotherapy will select patients who are candidates for organ-preservation. These patients will not undergo radical surgery and will instead be follow-up closely for tumor regrowth.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 94
• Est. completion date: April 16, 2024
• Est. primary completion date: April 16, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male and female patients with histologically confirmed diagnosis of rectal cancer localized 0 - 12 cm from the anocutaneous line as measured by rigid rectoscopy (i.e. lower and middle third of the rectum)

• Any MRI staged cT3 tumor or any cT1 cN+ or cT2 cN+ with nodal staging according to "SOP MRI"

• Staging requirements: High-resolution, thin-sliced (i.e. 3mm) magnetic resonance imaging (MRI) of the pelvis is the mandatory local staging procedure.

• Cross-sectional imaging of the abdomen and chest to exclude distant metastases.

• Aged at least 18 years. No upper age limit.

• WHO/ECOG Performance Status = 1

• Adequate hematological, hepatic, renal and metabolic function parameters

• Informed consent of the patient

Exclusion Criteria:

• Lower border of the tumor localised more than 12 cm from the anocutaneous line as measured by rigid rectoscopy

• cT4 tumors

• Positive lateral pelvic lymph nodes

• Distant metastases (to be excluded by CT scan of the thorax and abdomen)

• Preexisting fecal incontinence for solid stool

• Preexisting peripheral sensory neuropathy with functional impairment

• Preexisting myelosuppression reflected by a neutrophil count < 2.000/mm^3 and/or platelets < 100.000/mm^3

• Severe impairment of kidney function with a Creatinin Clearance < 30 ml/min)

• Prior antineoplastic therapy for rectal cancer

• Prior radiotherapy of the pelvic region

• Major surgery within the last 4 weeks prior to inclusion

• Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.

• Subject (male or female) is not willing to use highly effective methods of contraception according to the "Clinical trial fertility group"

• On-treatment participation in an interventional clinical study in the period 30 days prior to inclusion

• Previous or current drug abuse

• Other concomitant antineoplastic therapy

• Serious concurrent diseases, including neurologic or psychiatric disorders (incl. dementia and uncontrolled seizures), active, uncontrolled infections, active, disseminated coagulation disorder, severe liver function disorders

• WHO/ECOG Performance Status > 1

• Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) = 6 months before enrolment.

• Chronic diarrhea (> grade 1 according NCI CTCAE) Prior or concurrent malignancy = 3 years prior to enrolment in study (Exception: non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1), if the patient is continuously disease-free

• Known allergic reactions on study medication

• Known dihydropyrimidine dehydrogenase deficiency

• Medication inhibitors of the dihydropyrimidine dehydrogenase, such as Brivudin, Sorivudin and its analogues.

• Pernicious anemia or other anemias caused by Vitamin B-12 deficiency.

• Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule (these conditions should be discussed with the patient before registration in the trial).

• Additionally for hyperthermia cardiac pacemakers and metal implants in the proximity of the pelvis constitute a criterion for exclusion.

Related Conditions & MeSH terms

• Rectal Cancer
• Rectal Cancer Stage II
• Rectal Cancer Stage III
• Rectal Neoplasms

Intervention

Radiation:
• Radiotherapy
Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38

Drug:
• Chemotherapy
chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29. After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of: Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv

Other:
• Deep regional hyperthermia
Deep regional hyperthermia to the pelvis, total time 90 min, target temperature 41-42°C. Twice weekly, up to a total of 10 sessions within d1 and d38. Deep regional hyperthermia is offered at the centers in Tübingen and Erlangen.

Locations

Country	Name	City	State
Germany	University Hospital Erlangen	Erlangen
Germany	University Hospital Frankfurt	Frankfurt
Germany	University Hospital Tübingen	Tübingen
Germany	University Hospital Würzburg	Würzburg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Tuebingen

Country where clinical trial is conducted

Germany, 

References & Publications (3)

Gani C, Bonomo P, Zwirner K, Schroeder C, Menegakis A, Rödel C, Zips D. Organ preservation in rectal cancer - Challenges and future strategies. Clin Transl Radiat Oncol. 2017 Mar 23;3:9-15. doi: 10.1016/j.ctro.2017.02.002. eCollection 2017 Apr. Review. — View Citation

Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15. — View Citation

Schroeder C, Gani C, Lamprecht U, von Weyhern CH, Weinmann M, Bamberg M, Berger B. Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone. Int J Hyperthermia. 2012;28(8):707-14. doi: 10.3109/02656736.2012.722263. Epub 2012 Sep 24. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical complete response rate	Response to treatment is assessed on day 106 after the start of radiochemotherapy.; A clinical complete response is defined by standardized findings in rectoscopy, MRI and digital rectal examination	Day 106 after the start of treatment
Secondary	Local regrowth rate		4 years
Secondary	Safety of the treatment (toxicity assessment according to NCI CTCAE Version 4.0)		4 years
Secondary	Fecal incontinence according to Wexner-Vaizey Score	Possible scores range from 0 (perfect continence) to 24 (complete incontinence)	4 years
Secondary	Quality of life according to EORTC Quality of Life questionnaire - C30		4 years
Secondary	Quality of life according to EORTC Quality of Life questionnaire - CR29		4 years
Secondary	Frequency of Low anterior resection syndrome (LARS-scale)		4 years
Secondary	Surgical morbidity in patients undergoing surgery		up to 30 days after surgery
Secondary	Surgical complications in patients undergoing surgery		up to 30 days after surgery
Secondary	Pathological staging, tumor downstaging (assessed by ypTNM findings in relation to initial cTNM staging), tumor regression grading according to Dworak in patients undergoing surgery		Day 123 after the start of treatment
Secondary	R0 resection rate, rate of circumferential resection margin negativity (> 1mm) in patients undergoing surgery		Day 123 after the start of treatment
Secondary	Rate of sphincter-sparing surgery in patients undergoing surgery		Day 123 after the start of treatment
Secondary	Relapse-free survival (local / distant / overall)		4 years
Secondary	Overall survival		4 years